Biovail Puts Up $37.5M To Ditch Wellbutrin Antitrust Case

Law360, New York (July 23, 2012, 10:38 PM EDT) -- Biovail Corp., now part of Valeant Pharmaceuticals International Inc., agreed to pay $37.5 million Monday to settle direct purchasers' claims in antitrust multidistrict litigation alleging it conspired to stifle the market for a generic version of antidepressant Wellbutrin XL.

The settlement, which does not involve fellow defendant GlaxoSmithKline PLC and remains subject to court approval, would end years of litigation accusing GSK and Biovail of trying to monopolize the market for Wellbutrin by blocking and impeding generic competitors.

The proposed settlement comes three months after a...
To view the full article, register now.